Denali Therapeutics
DNLI
19.16
-0.12
-0.62%
Denali Therapeutics
US · DNLI
#2454 by market cap
Listed 2017
19.16
-0.12
-0.62%
Live - 5344 symbols - heartbeat 435s ago
· 2026-10-08 07:00
Pre-market
19.06
-0.52%
After-hours
19.16
0.00%
Overnight
19.16
0.00%
- Market cap
- 3.06B
- P/E (TTM)i
- -6.75
- P/Bi
- 3.67
- EPSi
- -2.97
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on DNLI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 4.3 percentage points.
Institutional ownership
- Held by institutions
- 99.03% -4.34pp
- Institutions
- 351 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund75.71%
Hedge Fund10.10%
VC/PE Fund7.83%
Individual/Insider2.97%
Public Company2.37%
Sovereign Wealth Fund1.78%
Private Company0.57%
Government Pension Fund0.52%
Insurance Company0.13%
Top holders as of 2026-06-30
T. Rowe Price Group, Inc.
12.08% · 19.32M sh
BlackRock
8.77% · 14.03M sh
Baillie Gifford
7.48% · 11.96M sh
Vanguard Capital Management, LLC
4.55% · 7.27M sh
State Street Global Advisors
4.41% · 7.05M sh
Temasek Holdings
4.39% · 7.01M sh
Vanguard Portfolio Management, LLC
4.05% · 6.48M sh
UBS Asset Management
3.93% · 6.28M sh
FMR
2.83% · 4.52M sh
Geode Capital Management, LLC
2.49% · 3.97M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Ryan Watts | Chief Executive Officer | 1.40% |
| Steve Krognes | Director | 0.51% |
| Alexander Schuth | Co-Founder, CFO, COO & Secretary | 0.42% |
| Jay Flatley | Independent Director | 0.22% |
| Julian Baker | Independent Chairperson | 0.21% |
| Peter Chin | Senior Vice President of Late Clinical Development & Medical Affairs | 0.13% |
| David Schenkein | Independent Director | 0.05% |
| Peter Klein | Independent Director | 0.02% |
| Jennifer Cook | Independent Director | 0.02% |
| Nancy Thornberry | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-03 | Peter Chin | Senior Vice President of Late Clinical Development & Medical Affairs | Open Market Disposition | -1,654 | $22.29 |
| 2026-09-01 | Nancy Thornberry | Independent Director | Automatic Disposition | -11,439 | $22.85–23.74 |
| 2026-08-31 | Alexander Schuth | Co-Founder, CFO, COO & Secretary | Automatic Disposition | -2,768 | $23.44 |
| 2026-08-11 | Ryan Watts | Chief Executive Officer | Other Disposition | -32,220 | -- |
| 2026-08-10 | Alexander Schuth | Co-Founder, CFO, COO & Secretary | Open Market Disposition | -2,857 | $25.07 |
| 2026-06-02 | Jay Flatley | Independent Director | Other Acquisition | +6,408 | -- |
| 2026-06-02 | Jay Flatley | Independent Director | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Julian Baker | Independent Chairperson | Other Acquisition | +12,816 | -- |
| 2026-06-02 | Julian Baker | Independent Chairperson | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | David Schenkein | Independent Director | Other Acquisition | +6,408 | -- |
| 2026-06-02 | David Schenkein | Independent Director | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Peter Klein | Independent Director | Other Acquisition | +6,408 | -- |
| 2026-06-02 | Peter Klein | Independent Director | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Jennifer Cook | Independent Director | Other Acquisition | +6,408 | -- |
| 2026-06-02 | Jennifer Cook | Independent Director | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Timothy Van Hauwermeiren | -- | Other Acquisition | +6,408 | -- |
| 2026-06-02 | Timothy Van Hauwermeiren | -- | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Steve Krognes | Director | Other Acquisition | +6,408 | -- |
| 2026-06-02 | Steve Krognes | Director | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Nancy Thornberry | Independent Director | Other Acquisition | +6,408 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:00:03 · For reference only, not investment advice and not tailored to your situation.